

## Serum lipoprotein (a) in diabetic patients with various renal function not yet on dialysis

Azar Baradaran<sup>1</sup>, Yahya Madihi<sup>2</sup>, Alireza Merrikhi<sup>3</sup>,  
Mahmoud Rafieian-Kopaei<sup>4</sup>, Hamid Nasri<sup>5</sup>

### ABSTRACT

To examine the association of serum lipoprotein(a)[Lp(a)] concentration with various demographic and biochemical indexes of diabetic patients, we conducted a study on type 2 diabetes mellitus (T2D) patients. Patients were under treatment with insulin injection or oral hypoglycemic agents with various creatinine clearances not yet on dialysis. We studied 122 patients, with a mean age of  $63 \pm 10$  years. The duration of diabetes was  $7.4 \pm 5.8$  years. In this cross-sectional study, serum Lp(a), HbA<sub>1c</sub>, body mass index (BMI) and creatinine clearance were assessed. The mean serum Lp(a) was  $22.2 \pm 24.7$  mg/dL (median: 18.3 mg/dL), and serum Lp(a) levels more than 30 mg/dL was found in 29 (23.8%) patients. A significant inverse correlation of serum Lp(a) with clearance of creatinine was observed. This study suggests that renal function is an independent determinant of serum Lp(a) in diabetic patients.

**KEY WORDS:** Lipoprotein(a), Diabetes mellitus, Creatinine clearance.

doi: [http://dx.doi.org/10.12669/pjms.291\(Suppl\).3533](http://dx.doi.org/10.12669/pjms.291(Suppl).3533)

### How to cite this:

Baradaran A, Madihi Y, Merrikhi A, Rafieian-Kopaei M, Nasri H. Serum lipoprotein (a) in diabetic patients with various renal function not yet on dialysis. *Pak J Med Sci* 2013;29(1)Suppl:354-357. doi: [http://dx.doi.org/10.12669/pjms.291\(Suppl\).3533](http://dx.doi.org/10.12669/pjms.291(Suppl).3533)

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### INTRODUCTION

Lipoprotein(a) [Lp(a)], is a macromolecule which consists of a glycoprotein apolipoprotein(a), which is disulfide linked to apolipoprotein B-100 on an LDL core.<sup>1-6</sup> Its concentrations are primarily genetically determined<sup>7-12</sup>, and various studies have shown that, high levels of Lp(a) in plasma, is an independent risk factor for premature atherosclerotic

coronary artery disease.<sup>10-16</sup> The normal metabolism and the role of this lipoprotein are not fully elucidated.<sup>14-21</sup> Several studies have shown, high concentrations of Lp(a) in diabetic patients, which has led to speculation that Lp(a) may contribute to the greatly increased incidence of vascular disease associated with diabetes.<sup>4,21</sup> However, considerable debate still remains, regarding the precise value of serum Lp(a) levels in type 2 diabetes (T2D) patients. In non-diabetic patients, renal disease correlates with elevated levels of Lp(a) that are normalized by kidney transplantation.<sup>2,16,18,20</sup> Kidney involvement is a frequent complication of diabetes that has prompted speculation that, kidney dysfunction is the principal cause of raised Lp(a) in T2D patients.<sup>2-7</sup> This study aimed to investigate the association of serum Lp(a) level with various indexes of demographic and biochemical of T2D patients.

### METHODOLOGY

**Patients:** This cross-sectional study was conducted on a group of T2D patients who were admitted in the hospital for controlling the diabetes with either insulin injection or oral hypoglycemic

1. Azar Baradaran,  
Department of Pathology,
  2. Yahya Madihi,  
Child Growth and Development Research Center,  
Isfahan University of Medical Sciences, Isfahan, Iran
  3. Alireza Merrikhi,  
Child Growth and Development Research Center,  
Isfahan University of Medical Sciences, Isfahan, Iran
  4. Mahmoud Rafieian-Kopaei,  
Medical Plants Research Center,
  5. Hamid Nasri,  
Dept. of Internal Medicine, Water & Electrolytes Research Center,  
Isfahan University of Medical Sciences, Isfahan, Iran.
- 1-3: Isfahan University of Medical Sciences, Isfahan, Iran.  
4, 5: Shahrekord University of Medical Sciences, Shahrekord, Iran
- Correspondence:  
Hamid Nasri,  
Professor, Department of Internal Medicine,  
Water & Electrolytes Research Center,  
Isfahan University of Medical Sciences, Isfahan, Iran. and  
Shahrekord University of Medical Sciences, Shahrekord, Iran.  
Email: hamidnasri@yahoo.com

agents. Exclusion criteria included presence of any infections and use of lipid-lowering medications. All patients signed consent forms for participation in this study.

**Laboratory tests:** After admission to hospital, detailed medical history was obtained, and careful physical exam was performed. Serum Lp(a) were measured by enzyme-linked immunosorbent assay kit (Macra® Lp(a) manufactured by Strategic Diagnostics Inc. for Trinity Biotech USA, Jamestown, NY, USA). Results were expressed in mg/dL; the intra- and inter assay coefficients of variation for this method were < 5% and < 10%, respectively. Serum Lp(a) levels of 30 mg/dL was considered as the threshold value of risk for its pathological effect. Serum glycosylated hemoglobine (HbA<sub>1c</sub>) was measured by chromatography method using Hb-Gold of UK; normal level in our laboratory is up to 6.1%. Levels of serum albumin (Alb), serum creatinine (Cr), blood urea nitrogen (BUN) total protein, triglyceride (TG), cholesterol (chol), and high density lipoprotein (HDL-C) were measured using standard methods. Body mass index (BMI) was assessed using the standard formula.<sup>22</sup> Serum LDL-C was calculated by friedewald's formula.<sup>23</sup> Creatinine clearance was evaluated from serum creatinine, age and body weight.<sup>24</sup>

**Statistical analysis:** Data are expressed as the mean  $\pm$  SD and median values. For correlations we used the partial correlation test. For comparison between females and males student's *t* test was used. To normalize of the serum Lp(a) data, the cube root of Lp(a) was assessed and used. All

analyses were performed with the SPSS statistical package (version 11.0 for Windows; SPSS, Chicago). Statistical significance was determined at value of  $p < 0.05$ .

## RESULTS

In Table-I the baseline characteristics of the study patients are shown. One hundred twenty two patients (40 males, 82 females) with a mean age of  $63 \pm 10$  years, was enrolled to this study. The mean duration of diabetes were  $7.4 \pm 5.8$  years (median: 6 years). The mean serum Lp(a) was  $22.2 \pm 24.7$  mg/dl (median: 18.3 mg/dl). Serum Lp(a) levels > 30 mg/dl was found in 29 patients (23.8%). The mean of creatinine clearance was  $64 \pm 24$ . We found a significant inverse correlation of duration of diabetes mellitus (DM) with creatinine clearance ( $r = -0.51$ ,  $p < 0.001$ ). A significant inverse correlation of serum Lp(a) with creatinine clearance ( $r = -0.19$ ,  $p = 0.03$ ) was seen. We did not find a significant correlation of serum Lp(a) with age, or DM, BMI, serum Alb, total protein, lipids or serum HgA<sub>1c</sub>.

## DISCUSSION

Our results demonstrated a significant inverse correlation of duration of DM and serum Lp(a) with creatinine clearance. There was no significant correlation of serum Lp(a) with age, BMI, serum Alb, total proteins, lipids and serum HgA<sub>1c</sub>. Serum Lp(a) levels > 30 mg/dl was found in 23.8% of patients. Recent studies suggest that Lp(a) can act as a marker for determining vascular or tissue injury.<sup>25</sup>

Table-I: Patients' data and laboratory tests of the 122 study patients.

Parameters	Minimum	Maximum	Mean $\pm$ SD	Median
Age (years)	25	84	63 $\pm$ 11	64
Duration of DM (years)	0.1	25	7.4 $\pm$ 6.8	6
BMI (kg/m <sup>2</sup> )	30	53	25.5 $\pm$ 4.5	25.3
Systolic blood pressure (mmHg)	100	180	138 $\pm$ 23	80
Diastolic blood pressure (mmHg)	50	130	83 $\pm$ 12	140
Creatinine clearance (ml/min)	10	110	64 $\pm$ 24	64
Lipoprotein(a) (mg/dl)	0.10	134	22.2 $\pm$ 24.8	18.3
Albumin (g/dl)	2.5	7.5	4.9 $\pm$ 1	4.9
Total protein (g/dl)	5	12.5	7.2 $\pm$ 0.9	7
HgbA <sub>1c</sub> %	3.9	13.5	7.6 $\pm$ 1.9	7.6
Cholesterol (mg/dl)	90	38.8	198 $\pm$ 52	192
Triglyceride (mg/dl)	37	580	183 $\pm$ 102	155
LDL-C (mg/dl)	44	210	112 $\pm$ 37	112
HDL-C (mg/dl)	19	128	47 $\pm$ 18	44

Recent findings have also demonstrated that Lp(a) is an independent risk factor for the progression of diabetic nephropathy in T2D patients.<sup>26,27</sup> Indeed macroalbuminuria was associated with raised plasma Lp(a) regardless of the marker used to identify kidney failure.<sup>28-42</sup> Moreover, altered kidney function, is a major determinant of raised Lp(a) levels in microalbuminuric and normoalbuminuric diabetics patients.<sup>34,35</sup> Increase in plasma Lp(a) levels was seen in various studies in nondiabetics.<sup>34-42</sup> Increased levels of Lp(a) is an independent risk factor for vascular disease in the general population and in diabetic patients.<sup>43-54</sup> In view of these findings, defining the relationship between renal complications and levels of serum Lp(a) in diabetic patients is mandatory.

### CONCLUSION

Our results suggest that serum Lp(a) concentration was associated with clearance of creatinine as a primary determinant of raised serum Lp(a) in diabetic patients. This has important implications for the increased susceptibility to vascular disease associated with Lp(a) in diabetic patients.

### ACKNOWLEDGEMENTS

This study is based on an MD thesis. This study has been conducted in the form of research project with the registration code of 312 and has been financially supported by the Research Deputy of Shahrekord University of Medical Sciences which is hereby sincerely appreciated.

**Conflict of interest:** The authors declared no competing interests.

### REFERENCES

- Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. *Circulation*. 1999;100(11):1154-1160.
- Baradaran A, Nasri H. Association of serum lipoprotein (a) with left ventricular hypertrophy in hemodialysis patients. *Indian J Nephrol*. 2004;14(2):41-45.
- Khajehdehi P. Turmeric: Reemerging of a neglected Asian traditional remedy. *J Nephropathology*. 2012;1(1):17-22.
- Nasri H. Association of serum lipoprotein (a) with hypertension in diabetic patients. *Saudi J Kidney Dis Transpl*. 2008;19(3):420-427.
- Kadkhodae M. Erythropoietin; bright future and new hopes for an old drug. *J Nephropathology*. 2012;1(2):81-82.
- Nasri H, Yazdani M. The relationship between serum LDL-cholesterol, HDL-cholesterol and systolic blood pressure in patients with type 2 diabetes. *Kardiol Pol*. 2006;64(12):1364-1368.
- Kooshki A, Taleban FA, Tabibi H, Hedayati M. Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients. *Ren Fail*. 2011;33(9):892-898.
- Gheissari A, Mehrasa P, Merrikhi A, Madihi Y. Acute kidney injury: A pediatric experience over 10 years at a tertiary care center. *J Nephropathology*. 2012;1(2):101-108.
- Aggarwal HK, Jain D, Lathar M, Yadav RK, Sawhney A. Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease. *Ren Fail*. 2010;32(6):647-652.
- Nasri H, Baradaran HR. Lipids in association with serum magnesium in diabetes mellitus patients. *Bratisl Lek Listy*. 2008;109(7):302-306.
- Einollahi B. Are acquired cystic kidney disease and autosomal dominant polycystic kidney disease risk factors for renal cell carcinoma in kidney transplant patients? *J Nephropathology*. 2012;1(2):65-68.
- Schaefer EJ, Lamon-Fava S, Jenner JL. Lipoprotein(a) levels and risk of coronary heart disease in men: The Lipid Research Clinics Coronary Primary Prevention Trial. *JAMA*. 1994;271(13):999-1003.
- Tolou-Ghamari Z. Nephro and neurotoxicity, mechanisms of rejection: A review on Tacrolimus and Cyclosporin in organ transplantation. *J Nephropathology*. 2012;1(1):23-30.
- Tabibi H, Imani H, Hedayati M, Atabak S, Rahmani L. Effects of soy consumption on serum lipids and apoproteins in peritoneal dialysis patients: a randomized controlled trial. *Perit Dial Int*. 2010;30(6):611-618.
- Topciu Shufta V, Begolli L, Kryeziu E. Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis. *Bosn J Basic Med Sci*. 2010;10(1):19-25.
- Ishibashi S. Lipoprotein(a) and atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2001;21(1):1-2.
- Assadi F. The epidemic of pediatric chronic kidney disease; the danger of skepticism. *J Nephropathology*. 2012;1(2):61-64.
- Nasri H, Baradaran A. Association of serum lipoprotein(a) with ultrasonographically determined early atherosclerotic changes in the carotid and femoral arteries in kidney transplanted patients. *Transplant Proc*. 2004;36(9):2683-2686.
- Tayebi Khosroshahi H. Short history about renal transplantation program in Iran and the world: Special focus on world kidney day 2012. *J Nephropathology*. 2012;1(1):5-10.
- Nasri H, Baradaran A. Association of Early Atherosclerotic Vascular Changes with Serum Lipoprotein (a) in Predialysis Chronic Renal Failure and Maintenance Hemodialysis Patients. *Saudi J Kidney Dis Transpl*. 2005;16(2):154-160.
- Armstrong VW, Cremer P, Eberle E. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: Dependence on serum LDL levels. *Atherosclerosis*. 1986;62(3):249-257.
- Baradaran A, Behradmanesh S, Nasri H. Association of body mass index and serum vitamin D level in healthy Iranian adolescents. *Endokrynol Pol*. 2012;63(1):29-33.
- Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of Low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. *Clin Chem* 1972;18(6):499-502.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976;16(1):31-41.
- Baradaran A, Nasri H, Ganji F. Association of serum lipoprotein(a) with intima-media thickness as a target-organ damage in essential hypertensive patients. *Iran Heart J*. 2004;5:55-63.

26. Boemi M, Sirolla C, Fumelli P, James RW. Renal disease as a determinant of increased lipoprotein concentrations in diabetic patients. *Diabetes Care*. 1999;22(12):2033-2036.
27. Heesen BJ, Wolfenbuttel BH, Leurs PB. Lipoprotein(a) levels in relation to diabetic complications in patients with non-insulin dependent diabetes. *Eur J Clin Invest* 1993;23(9):580-584.
28. Heller FR, Jamart J, Honore P. Serum lipoprotein(a) in patients with diabetes mellitus. *Diabetes Care*. 1993;16(5):819-823.
29. Durlach V, Gillery P, Bertin E. Serum lipoprotein(a) concentrations in a population of 819 non-insulin-dependent diabetic patients. *Diabet Metab*. 1996;22(5):319-323.
30. Tavafi M. Diabetic nephropathy and antioxidants. *J Nephropathology*. 2013;2(1):20-27.
31. Tolouian R, Hernandez GT. Prediction of Diabetic Nephropathy: The need for a sweet biomarker. *J Nephropathology*. 2013;2(1):4-5.
32. Rouhi H, Ganji F. Effect of N-acetyl cysteine on serum Lipoprotein (a) and proteinuria in type 2 diabetic patients. *J Nephropathology*. 2013;2(1):61-66.
33. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome: Relation to plasma albumin concentration, oncotic pressure and viscosity. *N Engl J Med*. 1985;312(24):1544-1548.
34. Mooser V, Seabra MC, Abedin M. Apolipoprotein(a) kringle 4-containing fragments in human urine: Relationship to plasma levels of lipoprotein(a). *J Clin Invest*. 1996;97(3):858-864.
35. Nasri H, Mortazavi M, Ghorbani A, Shahbazian H, Kheiri S, Baradaran A, et al. Oxford-MEST classification in IgA nephropathy patients: A report from Iran. *J Nephropathology*. 2012;1(1):31-42.
36. Sánchez-Niño MD, Ortiz A. Is it or is it not a pathogenic mutation? Is it or is it not the podocyte? *J Nephropathology*. 2012;1(3):152-154.
37. Ghorbani A, Rafieian-Kopaei M, Nasri H. Lipoprotein (a): More than a bystander in the etiology of hypertension? A study on essential hypertensive patients not yet on treatment. *J Nephropathology*. 2013;2(1):67-70.
38. Ruiz J, Thillet J, Huby T, James RW, Erlich D, Flandre P, et al. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. *Diabetologia*. 1994;37(6):585-591.
39. James RW, Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D. Lipoprotein(a) and vascular disease in diabetic patients. *Diabetologia*. 1995;38(6):711-714.
40. Rahimi Z. ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy. *J Nephropathology*. 2012;1(3):143-151.
41. Kari J. Epidemiology of chronic kidney disease in children. *J Nephropathology*. 2012;1(3):162-163.
42. Gheissari A, Hemmatzadeh S, Merrikhi A, Fadaei Tehrani S, Madihi Y. Chronic Kidney Disease in Children: A report from a tertiary care center over 11 years. *J Nephropathology*. 2012;1(3):159-164.
43. Hirata K, Saku K, Jimi S, Kikuchi S, Hamaguchi H, Arakawa K. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients. *Diabetologia*. 1995;38(12):1434-1442.
44. Solati M, Mahboobi HR. Paraoxonase enzyme activity and dyslipidemia in chronic renal failure patients. *J Nephropathology*. 2012;1(3):123-125.
45. Mohammadi Torbati P. Focal segmental glomerulosclerosis; collapsing variant. *J Nephropathology*. 2012;1(2):87-90.
46. Bordalo AD, Nobre AL, Dantas M, Cravino J. Elevated HDL is the main negative risk factor for coronary artery disease in the elderly patient with calcific aortic valve disease. *Rev Port Cardiol*. 2012;31(6):415-424.
47. Mubarak M. Collapsing focal segmental glomerulosclerosis: increasing the awareness. *J Nephropathology*. 2012;1(2):77-80.
48. Stancu CS, Toma L, Sima AV. Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis. *Cell Tissue Res*. 2012;349(2):433-446.
49. Sahni N, Gupta KL. Dietary antioxidants and oxidative stress in predialysis chronic kidney patients. *J Nephropathology*. 2012;1(3):134-142.
50. Nasri H. Hypertension and renal failure with right arm pulse weakness in a 65 years old man. *J Nephropathology*. 2012;1(3):130-133.
51. Baradaran A. Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues. *J Nephropathology*. 2012;1(3):126-129.
52. Khosravi A, Pourmoghaddas M, Ziaie F, Enteshari A, Khaledifa A, Bahonar A. Does lipoprotein (a) level have a predictive value in restenosis after coronary stenting? *Int J Prev Med*. 2011;2(3):158-163.
53. Kotani K, Tsuzaki K, Taniguchi N, Sakane N. LDL Particle Size and Reactive Oxygen Metabolites in Dyslipidemic Patients. *Int J Prev Med*. 2012;3(3):160-166.
54. Razavi AE, Ani M, Pourfarzam M, Naderi GA. Associations between high density lipoprotein mean particle size and serum paraoxonase-1 activity. *JRMS*. 2012;17(11): Page no missing.